Dr. Peter McCullough on JAMA’s recent underpowered Ivermectin study

“There’s a signal of benefit based on over 70 studies and over 33 randomized trials where there is about a 56% benefit….When someone pitches in a 500 patient trial.. not blinded, no placebo.. and the doctors decide the endpoint, which is how much oxygen patients get, that’s a biased endpoint. When the headlines say that the trial overturned the entire science on ivermectin, that’s clearly an overstatement.”

Z stack Protocol Adult